Skip to content

Uganda PrEP and Harm Reduction Evaluation

Implementation Science Research on PrEP Delivery and Costing Within Harm Reduction Services for People Who Use Drugs in Uganda

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05040308
Enrollment
300
Registered
2021-09-10
Start date
2022-02-11
Completion date
2025-12-31
Last updated
2025-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV-1-infection

Keywords

pre-exposure prophylaxis, substance use disorders

Brief summary

This is an evaluation of programs to integrate PrEP into existing services for PWUD. PrEP will be delivered according to Uganda national guidelines and data from national monitoring and evaluation forms will be leveraged to address key outcomes. Additionally, research components will be implemented to support greater understanding of PrEP use and experiences of participants engaged with the PrEP programs.

Detailed description

The first facility-based medication-assisted treatment (MAT) program (with methadone) in Kampala launched in 2020, providing opportunity to integrate pre-exposure prophylaxis(PrEP) as part of a comprehensive HIV prevention package. Additionally, a community-based needle and syringe exchange program (NSP) provides opportunity to integrate PrEP and meet priorities of PWID while building rapport between providers and end-users. With two different service models - integrating PrEP into facility-based MAT and community-based NSP - there is a great opportunity to optimize the integration of PrEP and other HIV prevention services for PWUD. By integrating PrEP into two existing programs (MAT and NSP), this study will determine uptake and persistence of PrEP use and leverage these programs to conduct costing research and budget impact analysis.

Interventions

OTHERIntegrating PrEP delivery

Integration of PrEP delivery services in NSP and MAT programs

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
Makerere University
CollaboratorOTHER
University of Washington
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
15 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Accessing services from any of the programs implementing the integrated PrEP program described in this protocol * Able and willing to provide informed consent * Age ≥15 years

Exclusion criteria

* Any clinical or chronic medical condition that in the opinion of the investigator would make the participant unsuitable for the study or unable to independently provide informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Rate of PrEP uptake12 months after enrollmentPrEP uptake will be measured through PrEP bottle inventory (bottles dispensed) in people who access NSP versus MAT.
PrEP retention12 months after enrollmentPrEP retention will be measured through study visit attendance among those who access NSP versus MAT.
PrEP adherence12 months after enrollmentPrEP adherence will be measured objectively through plasma tenofovir in people who access NSP versus MAT.

Secondary

MeasureTime frameDescription
To measure the impact of knowledge gained from training peers of PWUD on PrEP.Baseline (pre-training), immediately after training, and 3 months post trainingThe clinic staff will train up to 50 health care providers of PWUD on PrEP service delivery using the national curriculum on PrEP services delivery. We will administer a quantitative assessment of PrEP knowledge and experiences with service provision at three time points: 1. Before the training (Baseline survey), 2. immediately after training (Post training survey), and 3. \ 3 months post training (Exit survey).
To conduct a budget impact analysis for integrating PrEP into MAT and NSP programs.12 months post study enrollmentThe clinic staff will conduct micro costing c using activity-based approaches for costs incurred (clinic wide trainings, recruitment, service delivery, lab monitoring, PrEP support, and provision of PrEP) and costs averted (health costs saved by averting incident HIV infections). Cost data will also be collected from the study budget, public health clinic budgets, published government reports, and the health economics literature. Time and motion studies will be conducted by observing visits of people who are accessing services, and staff time spent on counseling, clinical procedures, and delivering PrEP.

Countries

Uganda

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026